/PRNewswire/ Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partnership with Medison in.
/PRNewswire/ Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partnership with Medison in.
Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe diseaseCollaboration to evaluate imlifidase as potential pre-treatment prior to the administration of gene therapy in Pompe disease for patients with neutralizing antibodies (NAbs).
/PRNewswire/ Hansa Biopharma AB, "Hansa", (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that.
/PRNewswire/ Hansa Biopharma AB "Hansa", (Nasdaq Stockholm: HNSA), the pioneer in IgG-cleaving enzyme technology for rare immunological conditions, today.